Market Trends of Global Inflammatory Bowel Disease (IBD) Diagnostic Industry
Endoscopy Segment is Expected to Account for the Highest Market Share
An endoscopy is a medical treatment that allows doctors to view the body. An endoscope is used in the endoscopy technique to inspect the interior of a hollow organ or cavity of the body. Endoscopes, unlike many other medical imaging procedures, are put directly into the organ.
According to the study titled " Capsule Endoscopy in Inflammatory Bowel Disease: When? To Whom?" published in December 2021, capsule endoscopy (CE) has proven to be a helpful diagnostic technique for IBD, particularly Crohn's disease (CD) capsule endoscopy (CE) produces high-resolution endoluminal pictures of the small bowel. As a result, the advantages of endoscopy over other techniques support the segment's growth during the forecast period.
In addition, key initiatives taken by the market players like mergers, acquisitions, and partnerships strengthen their product portfolio in the region, thereby driving the market. For instance, in November 2021, RoundTable Healthcare Partners' portfolio company, Healthcare Components Group ("HCG") acquired Endoscopy Development Company ("EDC") which will bring all endoscopy components under one shop in both the optical and flexible categories.
Thus, all factors mentioned above boost the segment growth over the forecast period.
North America Dominates the Market and Expected to do the same in the Forecast Period
North America currently dominates the market for inflammatory bowel disease and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. One of the reasons for market growth is that in the United States, a rising prevalence of IBD diseases and growing demand for early diagnosis as well as product launches by the key market players.
According to the study published in the National Library of Medicine by Christopher McDowell; in May 2022, for ulcerative colitis and Crohn's diseases, the incidence of inflammatory bowel disease (IBD) in North America has ranged from 2.2 to 19.2 cases per 100,000 people in a year and 3.1 to 20.2 cases per 200,000 people in a year respectively. Adult ulcerative colitis and Crohn's disease prevalence in the United States were 238 per 100,000 people and 201 per 100,000 people, respectively. Therefore, it is anticipated that the rising prevalence of IBD diseases in the nation will increase demand for its diagnosis and thus propel market expansion.
According to the study titled "Validation of the newly Food and Drug Administration-approved Buhlmann fCal Turbo assay for measurement of fecal calprotectin in a pediatric population" published in the Practical Laboratory Medicine in November 2020, the study concluded that the fCal Turbo assay has been helpful as a quick screening method for IBD disease monitoring and differential diagnosis.
Therefore, it is anticipated that the market will grow due to the rising prevalence of IBD diseases and the increase in research studies evaluating various IBD diagnostic techniques.
